Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors
- PMID: 25702616
- DOI: 10.1016/j.anndiagpath.2015.01.001
Comparison of World Health Organization 2000/2004 and World Health Organization 2010 classifications for gastrointestinal and pancreatic neuroendocrine tumors
Abstract
Gastroenteropancreatic neuroendocrine tumors (GEPNETs) were divided into 4 groups based on tumor diameter and stage in World Health Organization (WHO) 2000/2004 classification as well-differentiated endocrine tumor benign (WDETB), well-differentiated endocrine tumor with uncertain behavior (WDETUB), well-differentiated endocrine carcinoma (WDEC), and poorly differentiated endocrine carcinoma (PDEC). World Health Organization 2000/2004 was not widely accepted because of stage-related classification and the category of "uncertain behavior." The European NET Society proposed a grading classification and site-specific staging system in 2010. Gastroenteropancreatic NETs were divided into 3 groups as NET grade 1 (G1), NET grade 2 (G2), and neuroendocrine carcinoma (NEC) grade 3 (G3) based on mitoses and the Ki-67 index. We evaluated 63 GEPNET cases according to both classifications. We compared two classifications and the tumor groups in terms of prognostic parameters (diameter, mitosis, Ki-67 index, angioinvasion, perineural invasion, necrosis, and metastasis) and pathologic stage. All 14 cases diagnosed as PDEC were included in the NEC G3 according to WHO 2010. Seventeen cases were diagnosed as WDETB, 9 as WDETUB, and 23 as WDEC. There was statistically significant difference between these groups in terms of all prognostic parameters except for necrosis, mitosis, Ki-67 index, and grade. All WDETB cases, 89% of WDETUBs, and 87% of WDECs were included in the NET G1. There were 45 cases evaluated as NET G1 and 4 cases as NET G2 according to WHO 2010. Metastasis and perineural invasion were more common in NET G2, no significant differences in other parameters. In conclusion, WHO 2010 is easier to use, whereas WHO 2000/2004 shows higher correlation with prognosis. However, it includes benign and uncertain behavior categories, although small tumors with low proliferative activity can also cause metastases. All GEPNETs should be considered potentially malignant.
Keywords: Classification; Gastrointestinal tract; Neuroendocrine tumor; Pancreas.
Copyright © 2015 Elsevier Inc. All rights reserved.
Similar articles
-
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).Oncologist. 2018 Apr;23(4):422-432. doi: 10.1634/theoncologist.2017-0364. Epub 2018 Jan 12. Oncologist. 2018. PMID: 29330208 Free PMC article.
-
Comparison of WHO 2000 and WHO 2010 classifications of gastroenteropancreatic neuroendocrine tumors.Turk J Gastroenterol. 2014 Feb;25(1):81-7. doi: 10.5152/tjg.2014.6579. Turk J Gastroenterol. 2014. PMID: 24918137
-
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.Am J Surg Pathol. 2016 Sep;40(9):1192-202. doi: 10.1097/PAS.0000000000000662. Am J Surg Pathol. 2016. PMID: 27259015 Free PMC article.
-
Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications.Cancer Treat Rev. 2016 Nov;50:61-67. doi: 10.1016/j.ctrv.2016.08.006. Epub 2016 Aug 28. Cancer Treat Rev. 2016. PMID: 27636009 Review.
-
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.Oncologist. 2016 Oct;21(10):1191-1199. doi: 10.1634/theoncologist.2015-0476. Epub 2016 Jul 8. Oncologist. 2016. PMID: 27401895 Free PMC article. Review.
Cited by
-
Treatment of a mixed acinar-endocrine carcinoma with uptake on 68Gallium-DOTATOC positron emission tomography-computed tomography: A case report.Oncol Lett. 2017 Jul;14(1):547-552. doi: 10.3892/ol.2017.6242. Epub 2017 May 24. Oncol Lett. 2017. PMID: 28693204 Free PMC article.
-
Expression of Somatostatin Receptor Type 2A and PTEN in Neuroendocrine Neoplasms Is Associated with Tumor Grade but Not with Site of Origin.Endocr Pathol. 2016 Sep;27(3):179-87. doi: 10.1007/s12022-016-9436-5. Endocr Pathol. 2016. PMID: 27256098
-
Evaluating the ACS-NSQIP Risk Calculator in Primary GI Neuroendocrine Tumor: Results from the United States Neuroendocrine Tumor Study Group.Am Surg. 2019 Dec 1;85(12):1334-1340. Am Surg. 2019. PMID: 31908214 Free PMC article.
-
Evaluation of Survival Following Surgical Resection for Small Nonfunctional Pancreatic Neuroendocrine Tumors.JAMA Netw Open. 2023 Mar 1;6(3):e234096. doi: 10.1001/jamanetworkopen.2023.4096. JAMA Netw Open. 2023. PMID: 36976561 Free PMC article.
-
Pathologic Complete Response After Neoadjuvant Chemoradiation in a Patient with Gastric Neuroendocrine Cancer.Cureus. 2019 Jul 23;11(7):e5214. doi: 10.7759/cureus.5214. Cureus. 2019. PMID: 31565618 Free PMC article.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical